Anticancer immunotherapy has entered an era in which concepts no longer require validation, but in which an ever increasing immunological knowledge provides an embarrassingly large panel of choices in term of immune cells and mediators to test. Even focusing on T cell-mediated immunotherapy comes with difficult choices, concerning not only which specific T-cell lineage to promote (for instance, CD8^+^ vs. CD4^+^ T~H~1, T~H~2 or T~H~17 cells), but which cellular requirements to impose on different stages of the immune response. Indeed, the roles of T cells of a given lineage with varying differentiation statuses can change during the induction phase (for instance, at vaccination), at the effector stage, during chronic stimulation, and along with the establishment of long-term immunological memory.[@R1] Multiple issues related to tumor type and anatomical location further add to this complexity. Solid neoplasms are particularly resistant to T cell-based immunotherapy because the tumor stroma can resist penetration by T lymphocytes. Moreover, tumor-infiltrating T cells generally encounter an hostile and robustly immunosuppressive microenvironment. Along similar lines, the relatively low accessibility of the brain to immune cells may negatively impact the efficacy of cell-based immunotherapeutic strategies for the treatment of both primary and metastatic brain malignancies. Nonetheless, when a robust infiltration of neoplastic lesions by T cells can be achieved (be it spontaneous or induced by immunotherapy), this can favorably correlate with clinical outcome.[@R2] Therefore, T cell-based immunotherapy might stand out as an attractive modality for the treatment of brain tumors, especially if the potentially synergistic interactions between different T-cell subsets could be fully exploited.

The most direct approach to study the role of different immune cell subsets in anticancer therapy is upon adoptive cell transfer (ACT),[@R1] as this avoids the inevitable bias originating from adjuvants and/or other vaccine components. Moreover, in view of clinical applications, it may be advantageous to expand T cells under controlled culture conditions, and notably in the absence of tumor- or chemotherapy-derived deleterious and/or immunosuppressive factors. The opportunity to expand T cells in vitro also imposes a choice on culture conditions. Indeed, culture conditions can be modified to elicit specific phenotypic and functional traits that can be exploited for therapeutic purposes. Historically, ACT-based anticancer therapy has been developed around CD8^+^ T cells, as they can differentiate to become potent cytotoxic T lymphocytes that specifically lyse malignant cells expressing their cognate antigen. Together with the notion that many cancer cells constitutively express MHC class I, but not class II, molecules (at least in vitro), this focused the discovery of tumor-specific or tumor-associated antigens (TSAs and TAAs) on molecules that can be recognized by CD8^+^ T cells. Major advances regarding in vivo presented epitopes have been made in the context of glioblastoma.[@R3] Of course, immunologists have long recognized the critical "helper" role of CD4^+^ T cells, particularly at the priming step of CD8^+^ T-cell immune responses, when they functionally license dendritic cells and produce high levels of interleukin-2 (IL-2).[@R4] To exploit these functional properties of CD4^+^ T cells, "universal" (but not tumor-associated) CD4 epitopes such as the pan-DR helper T-cell epitope (PADRE) or peptides from the tetanus toxoid have been incorporated in cancer vaccines.[@R5] Following the administration of CD8^+^ T cells activated in vitro, the help of CD4^+^ T cells is no longer required at the induction stage, but rather to support persistence and effector functions. To this aim, CD4^+^ T cells must presumably co-localize with CD8^+^ T cells at effector sites. Thus, a profound understanding of the trafficking and functional interactions of CD4^+^ and CD8^+^ T cells at tumor sites is essential for the optimization of ACT protocols.

We have recently reported an optimal strategy to exploit CD4^+^ T cells for ACT in the context of brain tumors.[@R6] In line with the notion that the homing properties of CD4^+^ T cells are influenced by their functional polarization, in our hands T~H~1 polarized CD4^+^ T cells infiltrated an intracranial tumor far more efficiently than their T~H~2 counterparts ([Fig. 1A](#F1){ref-type="fig"}). This correlated with elevated expression levels of α4 integrin and chemokine (C-X-C motif) receptor 3 (CXCR3), two hallmarks of T~H~1 polarization.[@R7] The objective was to enhance the recruitment of CD8^+^ T cells to the brain and to augment their ability to secrete interferon γ (IFNγ) and tumor necrosis factor α (TNFα), and this could only be achieved when TAA-specific CD4^+^ T~H~1 cells were co-administered ([Fig. 1B](#F1){ref-type="fig"}). These results extend to the central nervous system earlier findings exploring the importance of CD4^+^ T-cell help in the immune response against extracranial tumors.[@R8]^,^[@R9] As for many other malignancies, only a few TSAs/TAAs recognized by CD4^+^ T cells have been characterized to date for human brain tumors. Our findings should therefore encourage a wave of antigen discovery aimed at identifying targets for synergistic CD4^+^ and CD8^+^ T cell-based anticancer immunotherapy. "Universal," tumor-associated helper peptides from telomerase are interesting candidates to test in this sense.[@R10]

![**Figure 1.** Synergic effects of tumor-associated antigen-specific CD4^+^ T~H~ cells and CD8^+^ T cells against brain cancer. (A) In vitro polarized T~H~1 cells preferentially infiltrate an intracranial tumor. (B) T~H~1 cells specific for a tumor-associated antigen enhanced the infiltration of neoplastic lesions by CD8^+^ T cells and the ability of the latter to secrete cytokines. (C) Both T~H~1 and T~H~2 T cells have therapeutic effects when co-administered with CD8^+^ T cells, potentially owing to in vivo repolarization. APC, antigen-presenting cell; IFNγ, interferon γ; IL, interleukin.](onci-2-e25772-g1){#F1}

In conclusion, the adoptive transfer of T cells for the immunotherapy of brain tumors does not require the clinically inconvenient approach of local delivery, since systemically delivered TAA-specific T~H~1 CD4^+^ and CD8^+^ T cells exert synergistic anticancer effects. But is T~H~1 polarization a required complexity? In some circumstances probably not, because we demonstrated that in long-term models of immunotherapy against brain cancer, even T~H~2 polarized CD4^+^ cells can synergize with CD8^+^ effector cells ([Fig. 1C](#F1){ref-type="fig"}). This may be because of the inherent plasticity of in vitro polarized T~H~1 or T~H~2 CD4^+^ T cells, which may repolarize in vivo, in appropriate microenvironments.
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